Toetal Solutions Raises $1.02 Million in New Financing

Toetal Solutions, Inc., a foot and ankle medical device company pioneering effective solutions for foot and ankle deformities, announced it has closed $1.02M in its initial round of financing, from Runway Healthcare, LP, a medical device accelerator.

Toetal Solutions notes that the proceeds from the funding will enable Toetal to rapidly scale the development of its flagship product, the Ziptoe™ Hammertoe System.

The Ziptoe™ Hammertoe System is designed to enable foot and ankle surgeons to address rigid hammertoe deformities with a simple, easy-to-use implant. The Ziptoe system features a proprietary deployable nitinol implant that comes sterile packed with all necessary disposable instrumentation to perform the procedure in any surgical setting.

“We’ve designed a product with physician input throughout every step of development. Our market research made it clear that the current product offerings for hammertoe fusion lacked efficacy or were too cumbersome to implant easily. Ziptoe’s design meets the core tenants of proper bone fusion: Active Compression, Complete Stability, and Zero Rotation. We are excited to enter this next phase of product development and get this simple and easy-to-use product in the hands of foot and ankle surgeons,” said Jeff O’Donnell, Jr., CEO, and Co-Founder of Toetal Solutions.

Dr. Steven S. Soondar, D.P.M. stated, “The Ziptoe is needed to allow foot and ankle surgeons a reproducible means to correct hammertoe deformities, creating compression across the fusion site while also allowing for easy revision if necessary.”

Runway Healthcare, LP solely funded this financing and has a majority ownership position in the company. Toetal Solutions is Runway Healthcare’s second portfolio company.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”